CSIMarket Company Name, Ticker, Customers, else..
 
Grail Inc   (NASDAQ: GRAL)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $79.3700 $-0.63 -0.787%
Day's High: $80.16999816894531 Week Perf: -3.84 %
Day's Low: $ 76.60 30 Day Perf: 15.77 %
Volume (M): 555,822 52 Wk High: $ 118.84
Volume (M$): $ 0 52 Wk Avg: $71.24
Open: $79.00 52 Wk Low: $30.82



 Market Capitalization (Millions $) 3,226
 Shares Outstanding (Millions) 41
 Employees 910
 Revenues (TTM) (Millions $) 156
 Net Income (TTM) (Millions $) -395
 Cash Flow (TTM) (Millions $) -61
 Capital Exp. (TTM) (Millions $) 1

Business Description


The company is a commercial-stage healthcare firm specializing in early cancer detection through its multi-cancer early detection test, Galleri. Galleri screens for multiple types of cancer using a blood draw, detecting cancer signals and predicting the specific organ or tissue of origin. The test is designed to identify cancers at an early, more treatable stage. The company has conducted extensive clinical trials and submitted a pre-market approval application to the FDA.


   Company Address: 1525 O’Brien Drive Menlo Park 94025 CA
   Company Phone Number: 694-2553   Stock Exchange / Ticker: NASDAQ GRAL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CDNA        5.49% 
DGX   -1.46%    
FTRE        0.33% 
GH   -2.55%    
LH   -1.97%    
NTRA   -1.76%    
• View Complete Report
   



Business Update

GRAIL, Inc. Sets Out on New Venture as It Begins Trading on Nasdaq Stock Exchange

Published Tue, Jun 25 2024 12:47 AM UTC

On June 25, 2024, the healthcare startup GRAIL, Inc. (NASDAQ: GRAL) officially commenced regular-way trading on the Nasdaq Stock Exchange, marking an important milestone in its journey. Formerly known as GRAIL, LLC, the Menlo Park-based company s listing allows investors and stakeholders to participate in its growth and future prospects.GRAIL, Inc. is a pioneering healthcare...
Business Update

GRAIL Ascends to Nasdaq A New Dawn for Cancer Detection and Investment

Published Mon, Jun 24 2024 8:47 PM UTC

By In a significant milestone that promises to reshape the landscape of biotechnology and retail trading alike, GRAIL, Inc., a company at the forefront of early cancer detection, is set to begin trading on the Nasdaq Stock Exchange tomorrow. Formerly known as GRAIL, LLC, the company has transitioned to GRAIL, Inc. and will use the ticker symbol GRAL. This move on June 25, 20...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 20.66
Price to Sales (Expected) -
Price to Book 1.29
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.93
Working Capital Ratio 11.74
Leverage Ratio (MRQ) 0.12
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -10.63 $
Revenues (TTM) 3.84 $
Cash Flow (TTM) -
Cash 1.71 $
Book Value 61.53 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 171,560
Net Income per Employee (TTM) -434,423
Receivable Turnover Ratio (TTM) 8.77
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.06

Profitability Ratios Current
Gross Margin (MRQ) 47.91 %
Operating Margin (MRQ) -332.88 %
Net Margin (MRQ) -228.48 %
Net Cash Flow Margin (MRQ) -442.28 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Grail Inc's Segments
Screening revenue    97.66 % of total Revenue
Screening revenue United States    94.95 % of total Revenue
Screening revenue International    2.71 % of total Revenue
Development Services    2.34 % of total Revenue
Development Services International    2.34 % of total Revenue
Screening revenue Commercial    92.35 % of total Revenue
Screening revenue Government    5.31 % of total Revenue
Development Services Commercial    2.34 % of total Revenue
Reportable Segment    100 % of total Revenue
Screening revenue Reportable Segment    97.66 % of total Revenue
Development services revenue    2.34 % of total Revenue
Development services revenue Reportable Segment    2.34 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.